Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artivion, Inc. filings document the regulatory record for a medical device company focused on aortic disease and related tissue preservation services. Recent Form 8-K disclosures furnish quarterly and annual operating results, clinical and regulatory updates, material agreements, and capital-structure matters, including credit-facility amendments and secured delayed draw term loan financing.
Proxy materials describe annual meeting voting, board governance, executive compensation, and shareholder matters. Other current reports document leadership appointments, material contracts, facilities-related agreements tied to the company’s operations, and disclosures connected to products such as aortic stent grafts, On-X mechanical heart valves, surgical sealants, and implantable cardiac and vascular human tissues.
Artivion, Inc. senior vice president of Regulatory and Quality, Andrew M. Green, filed an initial ownership report. He holds 60,259 shares of common stock directly, including 41,529 restricted stock units that each represent a contingent right to receive one share. He also holds stock options for 30,000 shares at an exercise price of $11.03 expiring in 2029 and options for 14,001 shares at $18.44 expiring in 2029.
ARTIVION, INC. director Anthony B. Semedo reported an internal restructuring of his holdings with no sale for value. On June 2, 2026, 6,325 shares of common stock were transferred from his directly held account to the Stacie Nelson and Anthony Semedo Living Trust for estate planning purposes.
After the transfer, he held 40,635 shares directly and 6,325 shares indirectly through the revocable living trust, which he and his spouse administer and may be deemed to beneficially own. An additional 600 shares were held indirectly through his spouse. These changes reflect only a shift in the form of ownership.
Borgstrom Marna P reported acquisition or exercise transactions in this Form 4 filing.
ARTIVION, INC. director Marna P. Borgstrom corrected a previously reported equity grant on an amended insider filing. The filing confirms a restricted stock award of 7,576 common shares granted on May 18, 2026, at no cost, which will vest on May 18, 2027, under the company’s Equity and Cash Incentive Plan.
After this correction, Borgstrom is shown as beneficially owning 56,664 common shares directly. The amendment states these changes fix administrative errors in the original Form 4 regarding the grant date, share amount, vesting date, and reported total holdings, with no other changes made.
SEMEDO ANTHONY B. reported acquisition or exercise transactions in this Form 4 filing.
ARTIVION, INC. director Anthony B. Semedo received a grant of 7,576 shares of common stock as a stock award, with no cash paid per share. This award is scheduled to vest on May 18, 2027 under the company’s Equity and Cash Incentive Plan.
After this grant, Semedo directly holds 46,960 shares of ARTIVION common stock and also indirectly owns 600 shares through his spouse, giving investors a clearer view of his equity-based compensation and overall stake in the company.
Salveson Jon W reported acquisition or exercise transactions in this Form 4 filing.
ARTIVION, INC. director Jon W. Salveson reported receiving a grant of 7,576 shares of common stock as a stock award. The shares were granted at no cash cost to him and are scheduled to vest on May 18, 2027 under the company’s Equity and Cash Incentive Plan. After this award, his direct holdings increased to 137,416 shares of Artivion common stock.
Hoff Elizabeth A reported acquisition or exercise transactions in this Form 4 filing.
ARTIVION, INC. director Elizabeth A. Hoff reported receiving a grant of 7,576 shares of common stock as equity compensation. The shares were awarded at no cash cost per share and increased her directly held position to 34,765 shares. According to the footnote, this restricted stock award is scheduled to vest on May 18, 2027 under the company’s Equity and Cash Incentive Plan, meaning she will fully earn the shares over time if vesting conditions are met.
Burbank Jeffrey H reported acquisition or exercise transactions in this Form 4 filing.
ARTIVION, INC. director Jeffrey H. Burbank received a grant of 7,576 shares of Common Stock on May 18, 2026, at no purchase price. The RSA grant is scheduled to vest on May 18, 2027, under the company’s Equity and Cash Incentive Plan. Following this award, he directly holds 61,372 shares of Artivion stock.
Bullock James reported acquisition or exercise transactions in this Form 4 filing.
ARTIVION, INC. director James Bullock reported receiving a grant of 7,576 shares of Common Stock as equity compensation. The award carried a price of $0.00 per share and increased his directly held stake to 76,223 shares. According to the disclosure, this restricted stock award vests on May 18, 2027 under the company’s Equity and Cash Incentive Plan, indicating it is a time-based compensation grant rather than an open-market purchase.
BEVEVINO DANIEL J reported acquisition or exercise transactions in this Form 4 filing.
ARTIVION, INC. director Daniel J. Bevevino reported receiving a grant of 7,576 shares of common stock as equity compensation. The award carried a price of $0.00 per share and increased his directly held position to 157,637 shares after the transaction. According to the footnote, this RSA grant will vest on May 18, 2027 under the company’s Equity and Cash Incentive Plan.
ARTIVION, INC. director Thomas F. Ackerman received an equity grant of 7,576 shares of common stock on May 18, 2026, at no cash cost, classified as a grant, award, or other acquisition under the company’s plan. These restricted shares vest on May 18, 2027, pursuant to the Equity and Cash Incentive Plan. Following this award, Ackerman directly holds 157,472 shares of Artivion common stock.